Coronavirus Notebook: 1.2bn Vaccines Produced Worldwide, ROVI To Double Moderna Capacity, Valneva starts UK Phase II/III trial
Executive Summary
The World Health Organization has updated progress with evaluations of two Chinese vaccines and Russia's Sputnik V, the UK has ordered 60 million more Pfizer/BioNTech doses, and the European Medicines Agency is looking at the use of baricitinib in COVID-19 patients requiring oxygen.
You may also be interested in...
UK Gathers Global Leaders For Pandemic Preparedness Project
New government funding to boost vaccine manufacturing and research into variant vaccines is being made available as part of the UK’s ambitious plans for a partnership to accelerate the availability of vaccines and other products for future pandemics.
Coronavirus Notebook: EMA Probes Janssen Vaccine Blood Clot Reports, UK Advises 12-Week Dosing Gap For Moderna
The AZ vaccine is now under EU scrutiny over capillary leak syndrome, while Valneva has reported positive results with its product. The global COVAX initiative has delivered more than 38 million doses of vaccines to over a hundred countries.
UK Steps Up Search For Vaccines Against ‘Variants Of Concern’
As the World Health Organization brands the Indian virus a “variant of concern,” the UK is planning to use a lab-grown virus variant in challenge trials of current and new vaccines, and is also investing in new variant vaccine testing facilities. A new study will use Oxford Immunotec’s T cell test to monitor people’s immunological response to infection or vaccination.